Literature DB >> 2559263

Accidental overdose of mitoxantrone in three patients.

W Siegert1, W Hiddemann, R Koppensteiner, T Büchner, M Essink, D Huhn, M Jung, L Marosi, T Martin, E Minar.   

Abstract

Mitoxantrone is a new effective antineoplastic agent with activity against a wide range of tumors. Compared with the anthracycline drugs doxo- and daunorubicin, it exhibits a clearly lower toxicity and, most importantly, a reduced cardiotoxicity. The analysis of the side-effects recorded after accidental overdosage of the drug gives additional insight into its tolerability. Here we describe our observations in three patients who inadvertently received 100 mg m-2 (two pts) and 183 mg m-2 (one pt) as single slow bolus injections. The main side-effects were moderate nausea and vomiting, shaking chills, and profound but reversible neutro- and thrombocytopenia. There was no immediate cardiac toxicity. One patient with extensive previous daunomycin exposure developed congestive heart failure after 4 months. Two patients were not evaluable for late cardiac complications because of early death due to tumor progression.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2559263     DOI: 10.1007/BF02985161

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  14 in total

1.  Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia.

Authors:  A D Ho; T Lipp; G Ehninger; P Meyer; M Freund; W Hunstein
Journal:  Cancer Treat Rep       Date:  1986-08

2.  Allergic reactions to mitoxantrone.

Authors:  W B Taylor; B M Cantwell; J T Roberts; A L Harris
Journal:  Lancet       Date:  1986-06-21       Impact factor: 79.321

3.  A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer.

Authors:  J C Allegra; T Woodcock; S Woolf; I C Henderson; S Bryan; A Reisman; G Dukart
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

4.  Mitoxantrone: an overview of safety and toxicity.

Authors:  L E Posner; G Dukart; J Goldberg; T Bernstein; K Cartwright
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  Clinical safety and tolerance of mitoxantrone.

Authors:  R J Crossley
Journal:  Semin Oncol       Date:  1984-09       Impact factor: 4.929

6.  Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations.

Authors:  B M Henderson; W J Dougherty; V C James; L P Tilley; J F Noble
Journal:  Cancer Treat Rep       Date:  1982-05

7.  Safety assessment of new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologic and ultrastructural pathology.

Authors:  B M Sparano; G Gordon; C Hall; M J Iatropoulos; J F Noble
Journal:  Cancer Treat Rep       Date:  1982-05

8.  Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients.

Authors:  M A Cornbleet; R C Stuart-Harris; I E Smith; R E Coleman; R D Rubens; M McDonald; H T Mouridsen; H Rainer; A T van Oosterom; J F Smyth
Journal:  Eur J Cancer Clin Oncol       Date:  1984-09

9.  High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.

Authors:  W Hiddemann; H Kreutzmann; K Straif; W D Ludwig; R Mertelsmann; R Donhuijsen-Ant; E Lengfelder; Z Arlin; T Büchner
Journal:  Blood       Date:  1987-03       Impact factor: 22.113

10.  Mitoxantrone, methotrexate, and 5-fluorouracil combination chemotherapy as first-line treatment in stage IV breast cancer.

Authors:  W R Bezwoda; C S Hesdorffer
Journal:  Cancer       Date:  1986-01-15       Impact factor: 6.860

View more
  3 in total

1.  Accidental iatrogenic intoxications by cytotoxic drugs: error analysis and practical preventive strategies.

Authors:  B Zernikow; E Michel; G Fleischhack; U Bode
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

Review 2.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

3.  Toxicity, outcome, and management of anthracycline overdoses in 16 dogs.

Authors:  Haylie C Lawson; Margaret L Musser; Rebecca Regan; Antony S Moore; Ann Hohenhaus; Brian Flesner; Chad M Johannes
Journal:  J Vet Intern Med       Date:  2021-11-25       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.